Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.

Levine SZ, Leucht S.

Schizophr Res. 2012 Nov;141(2-3):168-72. doi: 10.1016/j.schres.2012.08.030. Epub 2012 Sep 18.

PMID:
22995933
2.

Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.

Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ.

Schizophr Res. 2011 Aug;130(1-3):11-9. doi: 10.1016/j.schres.2011.03.015. Epub 2011 Apr 13. Erratum in: Schizophr Res. 2012 Feb;134(2-3):304.

PMID:
21489754
3.

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.

Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ.

BMC Psychiatry. 2011 Feb 9;11:23. doi: 10.1186/1471-244X-11-23.

4.

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM.

Schizophr Res. 2008 Jul;102(1-3):230-40. doi: 10.1016/j.schres.2008.02.021. Epub 2008 Apr 18.

PMID:
18423985
5.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
6.

Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.

Li M, Chen Z, Deng W, He Z, Wang Q, Jiang L, Ma X, Wang Y, Chua SE, Cheung C, McAlonan GM, Sham PC, Collier DA, Gong Q, Li T.

Psychol Med. 2012 Jul;42(7):1475-83. doi: 10.1017/S0033291711002157. Epub 2011 Oct 26.

PMID:
22030695
7.

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.

Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, Lieberman J.

Psychiatry Res. 2011 May 15;187(1-2):42-8. doi: 10.1016/j.psychres.2010.11.017. Epub 2010 Dec 18.

PMID:
21168920
8.

Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.

Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H.

Schizophr Res. 2012 May;137(1-3):141-6. doi: 10.1016/j.schres.2012.01.014. Epub 2012 Feb 7.

PMID:
22316567
9.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

10.

Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).

Khan A, Yavorsky WC, Liechti S, DiClemente G, Rothman B, Opler M, DeFries A, Jovic S.

J Clin Psychopharmacol. 2013 Feb;33(1):109-17. doi: 10.1097/JCP.0b013e3182776ebe.

PMID:
23277234
11.

Trajectories and antecedents of treatment response over time in early-episode psychosis.

Levine SZ, Rabinowitz J.

Schizophr Bull. 2010 May;36(3):624-32. doi: 10.1093/schbul/sbn120. Epub 2008 Oct 9.

12.

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

Schizophr Res. 2011 Dec;133(1-3):42-6. doi: 10.1016/j.schres.2011.09.018. Epub 2011 Oct 14.

PMID:
22000938
13.

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.

Docherty JP, Baker RA, Eudicone J, Mathew S, Marcus RN, McQuade RD, Mankoski R.

Schizophr Res. 2010 Jul;120(1-3):199-203. doi: 10.1016/j.schres.2010.03.040. Epub 2010 May 23.

PMID:
20547037
14.

Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM, Naber D.

Schizophr Res. 2010 May;118(1-3):176-82. doi: 10.1016/j.schres.2009.12.013. Epub 2010 Jan 15.

PMID:
20080036
15.

L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.

Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S.

J Psychiatr Res. 2014 Dec;59:125-31. doi: 10.1016/j.jpsychires.2014.08.016. Epub 2014 Sep 6.

PMID:
25227564
16.

Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.

Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S.

Schizophr Res. 2017 Apr;182:90-97. doi: 10.1016/j.schres.2016.10.027. Epub 2016 Oct 24.

PMID:
27789188
17.

The association between weight change and symptom reduction in the CATIE schizophrenia trial.

Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R.

Schizophr Res. 2011 May;128(1-3):166-70. doi: 10.1016/j.schres.2011.01.022. Epub 2011 Feb 21.

18.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
19.

Antipsychotic treatment response in schizophrenia.

Gardner KN, Bostwick JR.

Am J Health Syst Pharm. 2012 Nov 1;69(21):1872-9. doi: 10.2146/ajhp110559. Review.

PMID:
23111671
20.

Supplemental Content

Support Center